Home - Abcuro

Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease

news

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

November 13, 2023

Newton, Massachusetts, November 13, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart (ABC008) for the treatment

November 13, 2023

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body MyositisPress Releases

Targeting Highly Cytotoxic T Cells

Highly cytotoxic T cells have been implicated as mediators of tissue damage in many autoimmune diseases

ABC008 in Autoimmune Disorders

ABC008, an investigational monoclonal antibody, selectively depletes highly cytotoxic T cells

Inclusion Body Myositis

Inclusion body myositis (IBM) is a debilitating chronic, progressive disorder in which muscle is destroyed by highly cytotoxic T cells